Kyverna therapeutics, inc. investors with large losses are encouraged to contact shareholder rights law firm robbins llp for information about the kytx class action lawsuit

San diego , dec. 26, 2024 /prnewswire/ -- robbins llp reminds investors that a shareholder filed a class action against kyverna therapeutics, inc. (nasdaq: kytx) and certain of the company's senior executives and directors who signed the registration statement, effective february 7, 2024, issued in connection with the company's initial public offering ("ipo"). kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
KYTX Ratings Summary
KYTX Quant Ranking